Drug Type Monoclonal antibody |
Synonyms Anti-GREMl antagonist, Anti-Greml antibody UCB6114, Anti-Greml neutralising antibody + [2] |
Target |
Mechanism GREM1 inhibitors(Gremlin1 inhibitors), Intercellular signaling peptides and proteins inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Start Date09 Jul 2020 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 2 | BE | 30 Jan 2022 | |
Advanced Malignant Solid Neoplasm | Phase 2 | GB | 09 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 09 Jul 2020 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1/2 | 25 | (jeuhizmzji) = zsutvlmrwa egpeuvlzgi (wtxauvqmxo ) View more | Positive | 14 Apr 2023 |